Trial Profile
A Multicenter Open-label Non-comparative 2-Stage Phase 1a/1b Study to Assess the Safety and Pharmacokinetics of BCD-115 (JSC BIOCAD, Russia) in Combination With Endocrine Therapy in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs BCD 115 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biocad
- 11 Mar 2018 Status changed from recruiting to completed.
- 03 Mar 2017 New trial record